Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              A Bioequivalence Comparison at Steady State between the Newly Developed Once-Daily Extended Release Tablet Formulation and the Approved Twice-Daily Tablet Formulation of Deutetrabenazine

              Author:Sunzel, Eva-Maria   Rabinovich-Guilatt, Laura   Iyengar, Malini   Ruffo, Debra   Gutierrez, Maria   Gordon, Mark Forrest   Ghibellini, Giulia   

              Session Name:P2: Movement Disorders: Huntington's Disease and Chorea 2  

              Topic:Movement Disorders  

              Program Number:P2.015  

              Author Institution:Teva Pharmaceutical Industries Ltd , West Chester, PA  Teva Pharmaceutical Industries Ltd, Netanya, Israel  Teva Pharmaceutical Industries Ltd, Miramar, FL  

              Assessment of Dose Proportionality of Three Dose Strengths (6 mg, 12 mg and 24 mg) over the Clinical Dose Range (6-48 mg) of the Newly Developed Once-Daily Extended Release Tablet Formulation of Deutetrabenazine

              Author:Sunzel, Eva-Maria   Ghibellini, Giulia   Iyengar, Malini   Gutierrez, Maria   Ruffo, Debra   Gordon, Mark Forrest   Rabinovich-Guilatt, Laura   

              Session Name:P2: Movement Disorders: Huntington's Disease and Chorea 2  

              Topic:Movement Disorders  

              Program Number:P2.016  

              Author Institution:Teva Pharmaceutical Industries Ltd, West Chester, PA  Teva Pharmaceutical Industries Ltd, Miramar, FL  Teva Pharmaceutical Industries Ltd, Netanya, Israel